key: cord-0895650-a9phal6x
authors: Boonyasai, Romsai T.; Murthy, Vivek Krishna; Yuen-Gee Liu, Gigi; Garibaldi, Brian T.; Omron, Rodney; Brotman, Daniel J.; Streiff, Michael B.
title: Venous thromboembolism in hospitalized patients with COVID-19 receiving prophylactic anticoagulation
date: 2020-08-13
journal: Mayo Clinic Proceedings
DOI: 10.1016/j.mayocp.2020.08.014
sha: a3491847bebe75ff8a4a047271f9fc561d0894b8
doc_id: 895650
cord_uid: a9phal6x

nan

To the editor: Venous thromboembolism (VTE) has been reported in mechanically ventilated patients with severe SARS-CoV-2 infection . Two of the first 31 non-mechanically ventilated patients with moderate severity COVID-19 admitted to our hospital developed VTE while receiving uninterrupted prophylactic anticoagulation.

Patient A: a 54 year-old man with history of deep venous thrombosis (DVT) of the right lower extremity following patellar realignment surgery in his mid-20s. He presented with 7 days of rhinorrhea, cough, fatigue, and fever. He did not take medications and had never smoked. Before presentation, he had received cefuroxime and azithromycin without improvement. His temperature was 39.2 C, pulse 109 beats per minute, blood pressure 147/81 mm Hg, respiratory rate 22 breaths per minute, and oxygen saturation 92% breathing ambient air. He was alert and speaking in full sentences. He exhibited accessory muscle use while breathing. Posterior lung auscultation revealed inferolateral crackles bilaterally. Chest X-ray showed bilateral linear and patchy parenchymal opacities with basilar predominance. Electrocardiogram (ECG) showed sinus tachycardia. Laboratory tests were significant for white blood count 6,930 cells/cu mm, absolute lymphocyte count 720 cells/cu mm, platelet count 238,000 cells/cu mm, C-reactive protein 16.9 mg/dL, D-dimer 0.5 mg/L, and ferritin 1,386 ng/mL. Tests for influenza and respiratory syncytial virus were negative. Polymerase chain reaction (PCR) assay for SARS-CoV-2 was positive. COVID-19, although the optimal approach for inpatient VTE risk stratification and prophylaxis remains uncertain. 6, 7 Our observations suggest that moderate severity COVID-19 might also predispose hospitalized patients to higher VTE risk than standard RAMS would predict and might even precipitate acute VTE despite use of standard prophylactic-dose anticoagulant medications. It is instructive that standard VTE RAMs would have recommended thromboprophylaxis for only one of the two patients, and that neither patient met the D-dimer cut-off reported by Tang, et al. 5 Although our experience is too preliminary to draw firm conclusions, it brings into question whether current RAMs are adequate for guiding VTE thromboprophylaxis decisions in patients with COVID-19. This issue clearly warrants larger studies. In the interim, we propose that all patients hospitalized with COVID-19 receive pharmacologic VTE prophylaxis unless a contraindication to anticoagulation exists. We also suggest that the COVID-19 research agenda include studies to examine whether empiric therapeutic-strength anticoagulation improves outcomes compared to prophylactic anticoagulation, without leading to an untoward increased risk of major bleeding events.

A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score

Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. The New England journal of medicine

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up